Citi analyst Daniel Grosslight maintains $Agilon Health (AGL.US)$ with a sell rating, and adjusts the target price from $2.5 to $1.75.
According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 12.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Agilon Health (AGL.US)$'s main analysts recently are as follows:
The company's third-quarter results highlight the challenges in gaining insight into current trends and the limited capacity to manage adverse developments.
Agilon Health's stock has experienced a 23% decline following its Q3 report. This trend is anticipated to persist until the company demonstrates its ability to widen medical margins and precisely forecast medical costs, especially after a substantial reduction in its profitability forecasts.
The firm has revised its model post-Q3 results, indicating that intermediate liquidity concerns may pose a risk, alongside the possibility of further physician partner attrition.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析師Daniel Grosslight維持$Agilon Health (AGL.US)$賣出評級，並將目標價從2.5美元下調至1.75美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.0%，總平均回報率為12.3%。
此外，綜合報道，$Agilon Health (AGL.US)$近期主要分析師觀點如下：
該公司第三季度的業績突顯了在了解當前趨勢和應對不利發展方面的挑戰。
Agilon Health的股價在其第三季度報告後經歷了23%的下跌。預計這一趨勢將持續，直到公司展示擴大醫療利潤和準確預測醫療成本的能力，尤其是在實現盈利預測大幅下調之後。
公司已根據第三季度業績修訂了其模型，表明中期流動性問題可能構成風險，並可能進一步導致醫生合作伙伴的減少。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
